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Background: Beta-2 agonists are widely used in the treatment of
asthma and chronic obstructive pulmonary disease for their effect on
airway smooth muscle relaxation. They also act on skeletal muscle,
although their reported ergogenic effect is controversial.
Aim: To evaluate the in vitro effects of short-acting and long-acting
beta-2 agonists on adrenergic receptor (ADR) expression, hypertro-
phy, and atrophy markers, in a skeletal muscle cell line.
Methods: The C2C12 cell line was used as a model of skeletal
muscle differentiation. ADR messenger RNA expression was
evaluated in proliferating myoblasts, committed cells, and differen-
tiated myotubes, in basal conditions and after treatment with 1026 M
clenbuterol, salbutamol, salmeterol, and formoterol. Effect of beta-2
agonists on gene and protein expression of hypertrophy and atrophy
markers was assessed in differentiated myotubes.
Results: Our study shows that beta-2 ADR messenger RNA was
expressed and progressively increased during cell differentiation.
Beta-2 agonist treatment did not affect its expression. Skeletal
muscle hypertrophy markers (fast and slow myosin, myogenin) were
not modulated by any of the beta-2 agonists evaluated. However,
clenbuterol induced a signiﬁcant, dose-dependent downregulation of
skeletal muscle atrophy genes (atrogin-1, MuRF-1, and cathepsin L).
Conclusions: The reported ergogenic effect of beta-2 agonists,
if any, should be considered as drug-speciﬁc and not class-
speciﬁc and that of clenbuterol is mediated by the inhibition of the
atrophic pathway.
Key Words: beta-2 agonist, skeletal muscle hypertrophy/atrophy,
asthma, COPD, physical performance
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Because of their potent bronchodilator effect, both short-acting and long-acting beta-2 agonists (SABA and LABA)
are recommended by the international guidelines1 and widely
used in the current treatment of asthma and chronic obstruc-
tive pulmonary disease (COPD).2
Beta-2 agonists exert their pharmacologic effects through
speciﬁc G protein–coupled receptors (adrenergic receptors,
ADRs), classiﬁed in beta-1, beta-2, and beta-3 (ADRB1,
ADRB2, and ADRB3) preferentially expressed in cardiac tis-
sue, airway smooth muscle and lipocytes, respectively.3
In the airways, ADRB2 activation is followed by
a speciﬁc signal transduction pathway, which ultimately results
in an increase of cyclic adenosine monophosphate required for
airway smooth muscle relaxation and bronchodilation.3
ADRB2 are also present in human skeletal muscle,
even though their expression during muscle differentiation
has not yet been completely elucidated.4 Human skeletal mus-
cle undergoes a continuous remodeling process, which results
from a delicate balance between synthesis and breakdown of
skeletal muscle ﬁbers.5 This varies during growth, aging, and
health status, as shown by the expression of several genes and
related proteins, which are used as markers of muscle differ-
entiation, hypertrophy, and atrophy.6,7
It has been shown that beta-2 agonists may have a pro-
found effect on skeletal muscle turnover, both in vitro and
in vivo. Hinkle et al8 demonstrated that clenbuterol causes hy-
pertrophy and has antiatrophic effects in mice skeletal muscle.
Similarly, Delday and Maltin9 have shown that clenbuterol
increases the expression of myogenin in immobilized rat
muscles. Further studies indicated that clenbuterol also induces
a shift from slow to fast myosin ﬁbers in skeletal muscle.10
In humans, the administration of salbutamol and
salmeterol has been reported to have ergogenic effects.11–13
These would be beneﬁcial in patients with COPD, in whom
muscle atrophy and weakness are reported.14,15 On the other
hand, although at present, there is no evidence of a signiﬁcant
positive effect on physical performance,16 beta-2 agonists are
included in the World Anti-Doping Agency list of banned
substances and prohibited in asthmatic athletes, both in and
out of competition.17 An exception is represented for salbuta-
mol and salmeterol as inhalers, which can be used only after
a declaration of use in the presence of a documented diagnosis
of asthma.17 Despite the clinical relevance of the effects of
beta-2 adrenergic drugs on skeletal muscle, in vitro and in vivo
studies in this area are limited. Furthermore, the effects of
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a single beta-2 agent are often extrapolated to other beta-2
agonists and to different dosages and administration routes.
We report here the results of a study aimed at evaluating
the in vitro effects of the 2 major agonists, short-acting beta-2
agonist (SABA) (clenbuterol and salbutamol) and long-acting
beta-2 agonist (LABA) (formoterol and salmeterol), on the
expression of ADRB2 in a muscle cell line, as well as of some
relevant markers of muscle hypertrophy and atrophy.
As a muscle cell line, we used the C2C12 that we
recently validated as a model of in vitro skeletal muscle
differentiation by the analysis of muscle-speciﬁc differentia-
tion-dependent markers.18
METHODS
Cell Culture and Beta-2 Agonist Treatment
C2C12 mouse myoblasts were grown as described18
and plated at a density of 2.5 · 104 cells per milliliter in
growing medium (GM); myotube differentiation was induced
after 72 hours by switching 80%–90% conﬂuent cells in dif-
ferentiation medium (DM). Cells were harvested for molecu-
lar analysis at 24 and 48 hours (proliferating myoblasts) and
at 72 hours (D0, committed myoblasts) after seeding in GM
and at 2 and 4 days (D2 and D4) after switch in DM.
To study the effects of a beta-2 agonist treatment,
salbutamol, salmeterol, clenbuterol, and formoterol (Sigma-
Aldrich, Milan, Italy) were diluted in GM or DM and added to
the cell culture at the start of experiments and at D0. In
preliminary experiments using different concentrations of the
beta-2 agonists (1024 to 1028 M), 1026 M was shown to be the
optimal concentration to be used in further experiments.
RNA Extraction and Quantitative Reverse
Transcription Polymerase Chain Reaction
Total RNA was extracted and reverse-transcribed as
described.18 Quantitative polymerase chain reaction (qPCR)
was performed in ABI PRISM 7000 light cycler (Applied Byo-
sistems, Monza, Italy) using SYBR Greener qPCR SuperMix
for ABI Prism (Invitrogen, Milan, Italy) as indicated by the
manufacturer. All primers were optimized for real-time reverse
transcription PCR ampliﬁcation checking the generation of
a single amplicon in a melting curve assay and the efﬁciency
in a standard curve ampliﬁcation (.98% for each couple of
primers). Quantitative reverse transcription PCR sample value
was normalized for the expression of 18s messenger RNA
(mRNA). The relative level for each gene was calculated using
the 22DDCt method19 and reported as arbitrary units. In all
experiments, each sample was analyzed in triplicate. Sequences
of primers are given in Table 1.
Protein Extraction and Western Blot Analysis
Total protein was extracted as described.18 Total extracts
were separated in a sodium dodecyl sulfate polyacrylamide gel
and transferred to a nitrocellulose membrane. Transfer was veri-
ﬁed by Ponceau S staining. The membrane was blocked
60 minutes at room temperature with 1% or 5% nonfat dry milk
in Tris buffered saline (T-TBS; 50 mM Tris base, 0.9% NaCl,
Tween 20 0.001%; pH 7.4). Anti-skeletal myosind
fast and slowd(M4276 and M8421; Sigma-Aldrich), anti-
myogenin (M3559; Dako, Milan, Italy), anti-a-tubulin (T5168;
Sigma-Aldrich) antibodies were added and incubated overnight
at 48C. After a 30-minute incubation at room temperature, the
membrane was washed 3 times with T-TBS and incubated for 60
minutes at room temperature with horseradish peroxidase (HRP)
labeled anti-rat or anti-mouse (Jackson Immunoresearch, LiStar-
Fish, Milan, Italy) in 5% nonfat dry milk. The membrane was
then washed 3 times, and the antibodies were visualized using
ECL Western Blotting Detection Reagents (Amersham Bio-
sciences, Milan, Italy). Quantitative analysis was performed us-
ing Quantity One analysis software (Versadoc 1000; Biorad,
Milan, Italy); sample value was normalized for housekeeping
protein (a-tubulin) and is reported as arbitrary units.
Statistical Analysis
Data are presented as the mean 6 SD of 3 different
independent cell cultures in each experimental setting. Statis-
tical analysis was performed for all the aimed outcomes,
using a 2-way factorial analysis of variance and a 1-way
analysis of variance followed by a Bonferroni test. P values
,0.05 were considered statistically signiﬁcant.
RESULTS
Beta-Adrenergic Receptor Expression During
C2C12 Differentiation
We investigated the ADR mRNA expression and
modulation in proliferating myoblasts (24 and 48 hours),
TABLE 1. Sequences of Primer Pairs Used for qPCR Measurements
Name GENBANK Sense Primer Antisense Primer
18s X00686 CCCTGCCCTTTGTACACACC CGATCCGAGGGCCTCACTA
ADRB1 NM007419 GTAACGTGCTGGTGATCGTG AAGTCCAGAGCTCGCAGAAG
ADRB2 NM007420 GAGCACAAAGCCCTCAAGAC GTTGACGTAGCCCAACCAGT
Atrogin NM026346 GCAAACACTGCCACATTCTCTC CTTGAGGGGAAAGTGAGACG
Cathepsin L NM009984 GTGGACTGTTCTCACGCTCAAG TCCGTCCTTCGCTTCATAGG
Murf 1 NM001039048 ACCTGCTGGTGGAAAACATC CTTCGTGTTCCTTGCACATC
Myogenin NM0311891 AGCTGTATGAGACATCCCCC TTCTTGAGCCTGCGCTTCTC
MyHC-IIb BC052786 GAGCAGCTGGCGCTGAAGGG GATTTCTCCTGTCACCTCTC
MyHC IIx/d XM354615 TCAATGAGCTGACTGCGCAG CAAGCTGCCTCTTCAGCTCC
MyHC-I NM080728 AAGATCGTGTCCCGAGAGGG TTGTACAGCACAGCCGGCTC
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committed cells (D0), and mature myotubes (D2 and D4).
Both ADRB2 mRNA and, to a signiﬁcantly lesser extent,
ADRB1 (P , 0.001) mRNA were expressed by the C2C12
cell line at any time point, whereas no expression of ADRB3
was detected in our experimental conditions.
qPCR data normalized versus mRNA ADR basal
expression showed that ADRB2 mRNA progressively and
signiﬁcantly (P , 0.001) increased during the differentiation
process of the cell culture (5-folds from 24 to 48 hours, 2folds
from 48 hours to D0, and 1.5-fold from D0 to D2), remaining
high in terminally differentiated myotubes (Fig. 1).
Effect of Beta-2 Agonist Treatment on
ADRB2 Expression
To determine if beta-2 agonist treatment could induce
some ADRB2 modulation during the skeletal muscle differ-
entiation process, we grew C2C12 cells with a 1026 M con-
centration of different short-lasting and long-lasting beta-2
agonists (salbutamol, clenbuterol, salmeterol, and formo-
terol). The addition of 1026 M concentration of beta-2 ago-
nists did not signiﬁcantly change ADRB2 mRNA expression
throughout the whole differentiation process (Fig. 2).
Effect of Beta-2 Agonist Treatment on
Skeletal Muscle Hypertrophy
We treated C2C12 cells with equimolar concentrations
of salbutamol, clenbuterol, salmeterol, and formoterol, to
evaluate whether they could modulate the expression
of hypertrophic (myogenin and myosin heavy chain
isoforms, MyHCs) and atrophic genes (atrogin-1, MuRF1,
and cathepsin L).
FIGURE 1. ADRBs expression during cells differentiation. Time
course of ADRB1 and ADRB2 mRNA expression during cell
differentiation analyzed by qPCR. Cells were harvested for
molecular analysis at 24 and 48 hours (proliferating myoblasts)
and at 72 hours (D0, committed myoblasts) after seeding in GM
and at 2 and 4 days (D2 and D4) after switch in DM. The results
shown represent the mean of 3 independent experiments using
independent cell cultures in each experimental setting. Bars
symbolize qPCR data normalized versus ADRB1 mRNA
expression value in untreated cells. ADRB2 were significantly
more expressed than ADRB1 (P , 0.001). The significant
increase of ADRB2 expression (P , 0.001) refers to the previous
time point of culture (data normalized versus the baseline
values). ***P , 0.001.
FIGURE 2. Beta-2 agonists effects on ADRB mRNA
expression. Time course of ADRB2 mRNA expression by qPCR
in C2C12 cells grown in presence of 1026 M beta-2 agonists
treatment (at 48 hours, D0, and D4). Bars represent mean 6
SD of 3 different independent experiments.
FIGURE 3. Beta-2 agonists effects on myogenin mRNA and
protein expression. Western blot analysis of myogenin protein
expression after 1026 M beta-2 agonists treatment. A, Upper
panel: myogenin; lower panel: a-tubulin (loading control).
Lanes: 1, untreated cells; 2, clenbuterol-treated cells; 3,
formoterol-treated cells; 4, salbutamol-treated cells; 5,
salmeterol-treated cells. B, Graph of quantified data from
Western Blot experiments; bars show the mean 6 SD of
3 different independent experiments.
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Myogenin Expression
Beta-2 agonist exposure did not determine a signiﬁcant
modulation of myogenin mRNA expression (data not
shown). This lack of effect was also conﬁrmed at protein
level (Fig. 3).
Myosin Heavy Chains Expression
qPCR analysis revealed that during differentiation,
salbutamol, clenbuterol, salmeterol, and formoterol did not
affect MyHCs mRNA expression (data not shown). Western
blot analysis conﬁrmed data at protein level (Fig. 4).
Atrophic Genes Expression
qPCR analysis revealed that clenbuterol signiﬁcantly
decreased atrogin-1, MuRF1, and cathepsin L mRNA
expression (8-, 7.5-, and 9-folds, respectively) (Figs. 5A–C)
in a clear dose-dependent manner (Figs. 6A–C). On the con-
trary, salbutamol, salmeterol, and formoterol did not induce
any effect on the expression of the above skeletal muscle
atrophy markers (Figs. 5A–C).
DISCUSSION
To our knowledge, this is the ﬁrst study on the
expression and beta-2 agonist modulation of ADRB2 in
a skeletal muscle cell line in relation to subsequent differen-
tiation stages, as well as on the comparative effects of
different SABA and LABA at equimolar concentrations on
hypertrophy and atrophy genes.
Our data show that transcript encoding ADRB2 are
expressed in C2C12 cells in a differentiation-dependent
manner, concomitant with the acquisition of a mature phe-
notype. Therefore, this muscle cell line may represent
a useful model for studying the in vitro effects of different
beta-2 agonists on skeletal muscle and speciﬁc receptor
expression, as previously shown for different agonists.18
To study the in vitro effects of clenbuterol, salbutamol,
formoterol, and salmeterol, we used several genes and
proteins as markers of skeletal muscle differentiation, hyper-
trophy, and atrophy.
Myogenin is a transcriptional factor that strictly marks
terminal differentiated myotubes.20 The myosin heavy chains
(MyHCs) are terminally differentiated muscle cells markers.
In normal adult skeletal muscle ﬁbers, 4 MyHC isoforms
may be expressed: 1 slow (MyHC-1) and 3 fast (MyHC-IIa,
MyHC-IIb, and MyHC-IIx/d).21 We had previously
shown that C2C12 expressed MyHC-IIb, MyHC-IIx/d, and
MyHC-I mRNAs but not MyHC-IIa.18
Transcriptional upregulation or downregulation atro-
phy-related genes are a characteristic feature of muscle
atrophy; the most relevant atrogenes are 2 ubiquitin ligases
named atrogin-1/Mafbx and MuRF1.6 Another important
intracellular degradation mechanism in skeletal muscle is
autophagy.7 Cathepsin L is a lysosomal enzyme whose role
appears to be critical for the degradation of membrane pro-
teins and that is known to be upregulated during skeletal
muscle atrophy.7
All beta-2 agonists under investigation were shown to
have no effect on ADRB2 expression and on hypertrophy
genes and proteins studied. The apparent inconsistency of our
results with those of previous studies8,9 may be possibly due
to different experimental systems, conditions, and concentra-
tions of beta-2 agonists used. The 1026 M concentration we
used seemed to be optimal for ADRB2 receptor expression
and be related to in vivo drug concentrations of beta-2 ago-
nists administered for therapeutic purposes.
Clenbuterol showed a dose-dependent downregulation
of the atrophy markers tested. Therefore, the reported
ergogenic effect of clenbuterol8–10 is more likely due to the
inhibition of the atrophic pathway rather than an effect of the
drug on skeletal muscle hypertrophy.
FIGURE 4. Beta-2 agonists effects
on myosin heavy chains (MyHCs)
protein expression. A, Western
blotting analysis of MyHCs protein
expression in differentiated
myotubes. Upper panel is
a representative immunoblot
showing MyHC slow isoform
expression; middle panel is
a representative immunoblot
showing MyHC fast isoform;
a-tubulin (lower panel) was used as
loading control. Lanes: 1, untreated
cells; 2, clenbuterol-treated cells; 3,
formoterol-treated cells; 4,
salbutamol-treated cells; 5,
salmeterol-treated cells. B, C, Graph
of quantified data from Western Blot
experiments with MyHC slow (B)
and MyHC fast (C) isoforms.
Histograms show the mean 6 SD
of 3 different Western
blot quantifications.
WAO Journal  June 2012 Beta-2 Agonists and Skeletal Muscle
 2012 World Allergy Organization 69
The antiatrophic effect of clenbuterol was not shown
by salbutamol, formoterol, and salmeterol when used at
the same molar concentration. This ﬁnding indicates
that the reported ergogenic effect of beta-2 agonists is not
FIGURE 5. Beta-2 agonists effects on atrophic genes mRNA
expression. qPCR analysis of atrogin-1 (A), MuRF1 (B), and
cathepsin L (C) mRNA expression in terminally differentiated
C2C12 cells grown in presence of 1026 M beta-2 agonists or
in presence of vehicle alone (untreated). Bars represent
mean 6 SD of 3 different independent experiments; statistical
significance was analyzed between beta-2 agonists treated
versus untreated cells. *P , 0,01; **P , 0.001.
FIGURE 6. Dose-dependent effect of clenbuterol on mRNA
expression of atrophic genes. Atrophic genes mRNA
expression of atrogin-1 (A), MuRF1 (B), and cathepsin L (C) by
qPCR in terminally differentiated myotubes grown in presence
of 1024 M, 1025 M, 1026 M, 1027 M, or 1028 M clenbuterol
or in presence of vehicle alone. Bars represent mean 6 SD of 3
different independent experiments; statistical significance was
analyzed between beta-2 agonists treated versus untreated
cells. **P , 0.001.
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class speciﬁc but drug speciﬁc or related to the drug
concentration used.
It is always difﬁcult to extrapolate clinical consequen-
ces from in vitro studies to humans. However, our ﬁndings
may only allow some speculations in relation to the potential
beneﬁts of using beta-2 agonists for treating muscular
weakness in patients with COPD or to deny them in asthmatic
athletes because of a potential ergogenic effect.
In COPD, exertional dyspnea and limited exercise
tolerance represent major symptoms of the disease. Although
these are largely due to the impaired lung function, wasting
and dysfunction of both respiratory and peripheral muscles
have long been recognized as hallmarks of the disease and
important cofactors in inﬂuencing its morbidity and mortality,
independently from the decline of lung functions.15,22
Understanding the mechanisms of muscle impairment
is crucial to prospect adequate therapeutic intervention.
Among the several factors that contribute to muscle wasting
and dysfunction in patients with COPD,15 special attention
has recently been focused on systemic inﬂammation and its
effects on protein synthesis and degradation,23 although phys-
ical inactivity is likely to be a more relevant factor in causing
muscle weakness and possibly atrophy.24 However, the
potential favorable effect of beta-adrenergic agents on muscle
dysfunction in patients with COPD does not ﬁnd supporting
evidence neither from our data nor from interventional stud-
ies. Certainly, more adequate therapeutic approaches should
be used to treat muscle wasting in COPD.25
The reported ergogenic effect and the increasing use of
beta-2 adrenergic drugs in athletes26 induced the International
Olympic Committee in 2002 to deny the use of beta-2 adren-
ergic agents without a documented diagnosis of asthma based
on very strict criteria.27 However, at present, only salbutamol
and salmeterol are permitted as inhalers while all beta-2 ago-
nists (including both optical isomers where relevant) are pro-
hibited; salbutamol (maximum 1600 mm over 24 hours),
formoterol (maximum 36 mm over 24 hours), and salmeterol
are permitted when taken by inhalation in accordance with the
manufacturers’ recommended therapeutic regimen.17 This
restriction might prevent adequate the new rule answers to
the concern, previously expressed by our group and other
authors, that the strict World Anti-Doping Agency regulations
could exclude from treatment, according to the Global Initia-
tive for Asthma (GINA) guidelines, in athletes with asthma or
exercise-induced bronchoconstriction but actual negative
challenge tests to prove it.28 In fact, there is no evidence of
a positive effect of beta-adrenergic agonists on physical per-
formance.16 Moreover, our data do not support any ergogenic
effect except for clenbuterol. Accordingly, restriction of beta-
2 adrenergic agents in asthmatic athletes should rather be
based on their potential effects on tolerance29 and cardiovas-
cular side effects (particularly for LABA),30,31 rather on the
fear of a class-speciﬁc effect on the skeletal muscle.
In conclusion, our data indicate that the C2C12 cell line
may represent a useful model to study the in vitro effects of
beta-2 adrenergic agents on differentiation, hypertrophy, and
atrophy of the skeletal muscle. In this model, clenbuterol,
salbutamol, formoterol, and salmeterol do not exert any effect
either on the expression of ADRB2 receptors or on the genes
and proteins tested as markers of hypertrophy. Only clenbu-
terol shows a signiﬁcant dose-dependent inhibitory effect on
the atrophic pathway, which might be responsible for the
ergogenic effect reported for this molecule.
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